Skip to content

Study · Case report or series · n = 1 · 2025

1 result

The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.

Abdulraheem A, Shukri D, Altork N, Afzal U, Abu-Rumaileh M, Meighani A

Cureus16 Feb 2025

PMID40104488 (opens in a new tab)PMCIDPMC11919247 (opens in a new tab)DOI10.7759/cureus.79105 (opens in a new tab)PepBankPUB-40104488
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Colonoscopy (CLN) is a common procedure for colon cancer screening and diagnosing various conditions. Acute cholecystitis (AC), though rare, has been reported as a complication. We present a 66-year-old female on semaglutide for obesity who developed AC within 72 hours post-CLN. Considering the increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their impact on gallbladder motility, these medications may contribute to this complication. Future research is crucial to investigate whether a washout period for GLP-1 agonists before CLN is needed to reduce the risk of AC, if such a risk exists.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 66-year-old woman on semaglutide for obesity developed acute cholecystitis within 72 hours after a colonoscopy.

    In plain wordsOne woman who took semaglutide for obesity had gallbladder inflammation within 72 hours after a colonoscopy. This does not show that semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    Not applicableAcute cholecystitis after colonoscopy in a patient on semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present a 66-year-old female on semaglutide for obesity who developed AC within 72 hours post-CLN.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.